Caas Capital Management LP Bristol Myers Squibb CO Call Options Transaction History

Caas Capital Management LP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Jul 15, 2024	BUY	$40.25 - $52.99 $213,325 - $280,847	5,300 New	5,300 $220,000
Q4 2023 Feb 14, 2024	BUY	$48.48 - $57.85 $72,720 - $86,775	1,500 New	1,500 $76,000
Q2 2022 Aug 15, 2022	SELL	$72.62 - $79.98 $704,414 - $775,806	-9,700 Reduced 38.49%	15,500 $1.2 Million
Q1 2022 May 13, 2022	SELL	$61.48 - $73.72 $37.8 Million - $45.3 Million	-615,000 Reduced 96.06%	25,200 $1.84 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $18.6 Million - $21.6 Million	-345,900 Reduced 35.08%	640,200 $39.9 Million
Q3 2021 Nov 15, 2021	BUY	$59.17 - $69.31 $20.5 Million - $24.1 Million	347,100 Added 54.32%	986,100 $58.3 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $39.6 Million - $43.1 Million	639,000 New	639,000 $42.7 Million

2,536

1.47B

31.6M

35M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $125B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.